Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. Januar 2013 07:30 ET | Quelle: Boston Therapeutics, Inc.

Boston Therapeutics Announces Clinical Study Final Results Indicate That SUGARDOWN(R) Reduced the Post-Meal Elevation of Blood Glucose by up to 61% in Healthy Volunteers

MANCHESTER, NH--(Marketwire - Jan 28, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrates to treat diabetes and...
19. Dezember 2012 07:30 ET | Quelle: Boston Therapeutics

Boston Therapeutics Approved in France to Initiate a Clinical Trial With SUGARDOWN(R) in Patients With Type II Diabetes

MANCHESTER, NH--(Marketwire - Dec 19, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of complex carbohydrate therapeutics to...
29. November 2012 07:00 ET | Quelle: Boston Therapeutics

Boston Therapeutics to Present Corporate Update at the SeeThruEquity Smallcap & Microcap Investor Summit

MANCHESTER, NH--(Marketwire - Nov 29, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of complex carbohydrate therapeutics to treat...
14. November 2012 15:39 ET | Quelle: Boston Therapeutics

Boston Therapeutics Reports Third Quarter and Nine Months 2012 Financial Results

MANCHESTER, NH--(Marketwire - Nov 14, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) SUGARDOWN® sales increased approximately 700% in the first nine months...
14. November 2012 08:15 ET | Quelle: Boston Therapeutics

Boston Therapeutics' Newly Appointed Chief Operating Officer Invests $625,000 in the Company's S-1 Financial Offering

MANCHESTER, NH--(Marketwire - Nov 14, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes...
13. November 2012 08:15 ET | Quelle: Boston Therapeutics

Boston Therapeutics Names Jonathan B.Rome Chief Operating Officer

MANCHESTER, NH--(Marketwire - Nov 13, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes...
04. Oktober 2012 07:01 ET | Quelle: Boston Therapeutics

Boston Therapeutics Wins FDA Approval to File an Abbreviated New Drug Application for PAZAMET(TM) to Treat Diabetes

MANCHESTER, NH--(Marketwire - Oct 4, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes and...
24. September 2012 11:51 ET | Quelle: Boston Therapeutics, Inc.

Boston Therapeutics Announces Filing of S-1 Registration Statement

MANCHESTER, NH--(Marketwire - Sep 24, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes...
14. August 2012 13:48 ET | Quelle: Boston Therapeutics, Inc.

Boston Therapeutics Reports Second Quarter and Six Months 2012 Financial Results

MANCHESTER, NH--(Marketwire - Aug 14, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) (OTCBB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate...
16. Juli 2012 07:00 ET | Quelle: Boston Therapeutics, Inc.

Boston Therapeutics to Present Corporate Update at the SeeThruEquity Microcap Investor Forum

MANCHESTER, NH--(Marketwire - Jul 16, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE)(OTCBB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to...

Vorherige Seite

Nächste Seite